Home Newsfeeds Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

byBenzinga Newsdesk

October 14, 2022

1 minute read

Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61.

Stronger US Dollar Takes The Toll – Industrial Conglomerate Teledyne’s Sales Up 2.9%, But Misses Estimate

By Nabaparna Bhattacharya

October 25, 1:49 PM

Teledyne Technologies Incorporated (NYSE: TDY) reported Q3 FY23 sales growth of 2.9% year-over-year to $1.403 billion,

TDY

Analyst Ratings

Breaking Down Western Midstream: 4 Analysts Share Their Views

By Benzinga Insights

May 7, 8:00 AM

Western Midstream (NYSE:WES) has been analyzed by 4 analysts in the last three months, revealing a diverse range…

WES

Investor Sentiment Declines Further After Dow Settles Lower

By Lisa Levin

March 9, 3:37 AM

The CNN Money Fear and Greed index showed another decline in overall sentiment among US investors. US stocks closed mixed on Wednesday after recording sharp losses in the previous session following comments from Federal Reserve Chair Jerome Powell.

House Of The Dragon Or Lord Of The Rings: The Rings Of Power — Which Do Benzinga Followers Prefer?

By Chris Katje

August 22, 3:12 PM

Two of the most anticipated new television series are launching on streaming platforms in August and September.

AMZN

Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61

Related Posts

Stronger US Dollar Takes The Toll – Industrial Conglomerate Teledyne’s Sales Up 2.9%, But Misses Estimate

Breaking Down Western Midstream: 4 Analysts Share Their Views

Investor Sentiment Declines Further After Dow Settles Lower

House Of The Dragon Or Lord Of The Rings: The Rings Of Power — Which Do Benzinga Followers Prefer?